Table 2.
Efficacy of olaparib versus placebo with respect to progression-free survival (ITT, PP and Cox adjusted populations) and overall survival.
| Olaparib (n=32) | Placebo (n=38) | HRd | p-valuec | |
|---|---|---|---|---|
| Progression-free survival events - N (%) | 31 (97) | 35 (92) | ||
| Progression-free survival (weeks) -median (IQR) | ||||
| ITT population | 16.6 (7.1–21.7) | 12 (5.6–18.7) | 0.83 (–1.02) | 0.23 |
| PP population | 16.6 (7.6–18.3) | 12.0 (5.6–18.7) | 0.86 (1.06) | 0.28 |
| Cox model adjusteda | 16.6 (7.1–21.7) | 12 (5.6–18.7) | 0.73 –0.91) | 0.11 |
| Cox model adjustedb | 16.6 (7.1–21.7) | 12 (5.6–18.7) | 0.79 (1.02) | 0.22 |
| Overall survival (weeks) - median (IQR) | ||||
| ITT population | 59.4 (38.7–67.9) | 31.3 (22.4–58.6) | 0.68 (0.37–1.26) | 0.22 |
a
Adjusted for stratification factors (smoking and histology).
b
Adjusted for stratification factors, T-stage, and N-stage.
c
One-sided p-values for progression-free survival (PFS). Two-sided p-value for overall survival (OS).
d
PFS hazard ratio (HR) 80% one-sided confidence interval (CI) upper limit and for OS HR two-sided 95% CI.